Table 1.

CML patients’ characteristics

Patient	Sex	Age at diagnosis (years)	Date of Diagnosis	Diagnosis	Translocation	Start of therapy	Therapy mg/die
1	M	59	21/02/2006	CML	t(9;22)(q34;q11) p210 b2a2	07/03/2006	IM 400 mg/die
2 +	M	66	06/06/2005	CML	t(9;22)(q34;q11) p210 b2a2	17/06/2005	IM 400 mg/die
3	M	60	20/05/2005	CML	t(9;22)(q34;q11) p210 b2a2	25/05/2005	IM 400 mg/die
4	M	50	30/03/2005	CML	t(9;22)(q34;q11) p210 b2a2	12/04/2005	IM 400 mg/die
5	F	71	03/02/2005	CML	t(9;22)(q34;q11) p210 b2a2	14/02/2005	IM 800 mg/die
6	F	63	02/12/2004	CML	t(9;22)(q34;q11) p210 b2a2	21/12/2004	IM 400 mg/die
7	M	52	8/10/2004	CML	t(9;22)(q34;q11) p210 b2a2	12/10/2004	IM 400 mg/die
8	M	60	30/05/2005	CML	t(9;22)(q34;q11;q24) p210 b2a2	08/06/2005	IM 400 mg/die
9	F	70	13/09/2007	CML	t(9;22)(q34;q11) p210 b2a2	24/09/2007	IM 400 mg/die
10	F	70	02/10/2007	CML	t(9;22)(q34;q11) p210 b2a2	20/10/2007	IM 400 mg/die
11a	M	66	03/08/2006	B-ALL	t(9;22)(q34;q11) p190	02/09/2006	IM 600 mg/die
12	M	74	12/07/2010	CML	t(9;22)(q34;q11) p210 b3a2	16/07/2010	IM 400 mg/die
13	F	20	04/08/2010	CML	t(9;22)(q34;q11) p210 b3a2	Not available	Not available
14b	F	49	20/08/2010	CML	t(9;22)(q34;q11) p210 b3a2	25/08/2010	IM 400 mg/die
15	M	48	02/11/2010	CML	(X;9;22)(p11;q34;q11)(ABL + BCR + ;ABL+BCR-) p210 b2a2	05/11/2010	IM 400 mg/die
16	F	67	16/12/2010	CML	t(9;22(q34;q11) p210 b3a2	21/12/2010	IM 400 mg/die

^aPatients 2 and 11 died in 2010 and 2009, respectively

^bBCR-ABL1 coordinates for patient 14 were taken from the derivative chromosome 9